Overview

Study on TSR-042 in Advanced Clear Cell Sarcoma

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).

Phase:

Phase 2

Details

Lead Sponsor:

Italian Sarcoma Group

Collaborator:

GlaxoSmithKline